Effects of multimodal rheumatologic complex treatment for 16 days - a monocentric prospective study

• Conditions: Degenerative disorders like gonarhrosispatients with Primary fibromyalgiaevery Patient treated with MRCT at our centre; M06.90; M45.00; M35; L40.5; Other systemic involvement of connective tissue; Arthropathic psoriasis

• Registration Number: DRKS00021261
• Lead Sponsor: Campus Kerckhoff der Justus-Liebig-Universität Gießen

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Completion: 2019-06-01
• Study Start: 2020-04-06
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 124

Inclusion Criteria

patient, who are treated with MRCT
classification criteria of disease need to be fulfilled

Exclusion Criteria

missing written study consent

Study & Design

• Study Type: observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Change in pain levels measured by a numeric rating scale (0-10) before and after a 16 day MRCT period

Secondary Outcome Measures

Name	Time	Method
Change before and after a 16 day MRCT period<br>- functional health (FFbH, HAQ, BASFI)<br>- disease activity (DAS28, BASDAI, WOMAC, AUSCAN, FIQ)<br>- Cytokinlevels of IL10, TNF, IL6, IL17, IL1<br><br>Change before MRCT and 12 weeks after discharge:<br>- functional health (FFbH, HAQ, BASFI)<br>- disease activity (DAS28, BASDAI, WOMAC, AUSCAN, FIQ)<br>- Cytokinlevels of IL10, TNF, IL6, IL17, IL1<br><br>Change after MRCT and 12 weeks after discharge<br>- functional health (FFbH, HAQ, BASFI)<br>- disease activity (DAS28, BASDAI, WOMAC, AUSCAN, FIQ)<br>- Cytokinlevels of IL10, TNF, IL6, IL17, IL1